Bupropion is an antidepressant of the aminoketone class that is chemically unrelated to any other known antidepressant agent. In the treatment of major depressive disorder (MDD), bupropion has shown comparable therapeutic efficacy to selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs). Bupropion effectiveness in treating co-morbid fatigue, hypersomnia, anhedonia, and mild to moderate anxiety symptoms (contrary to common clinician beliefs) associated with MDD is well documented. It is generally well tolerated with minimal undesirable side effects associated with antidepressants, such as sexual dysfunction and weight gain. Bupropion has shown effectiveness in augmentation as well as in switching strategies of antidepressant medications. Due to its favorable side-effect profile, bupropion has been used in the treatment of geriatric depression with good therapeutic efficacy and health outcome measurements. Bupropion has also shown usefulness as a smoking cessation agent and in treating depression in patients with medical co-morbidities such as asthma and HIV. Limitations of use include individuals at risk for seizures and patients with eating disorders.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
Thank you very much for the positive learning experience in publishing with you. It has been a wonderful experience from submission to final acceptance and publication in the International Journal of Insect Science. We are grateful to the editorial team for developing our manuscript into a valuable scientific paper through a well-formulated and quick reviews. The team was dedicated, quick and always available to respond positively to our demands. We are also thankful for the ...